Campbell Murray

Director/Board Member at LUMOS PHARMA, INC.

50 year

Health Technology

Commercial Services

Finance

Profile

Campbell Murray is the founder of Double Point Ventures LLC, founded in 2023, serving as Senior Advisor.
Current jobs include Executive Director at Lumos Pharma, Inc., Director at BioRelix, Inc., Director at Neurovance, Inc., and Managing Director at Novartis Venture Funds (USA) since 2005.
Former jobs include Chairman at Euthymics Bioscience, Inc., Director at Alios BioPharma, Inc., Rein Therapeutics, Inc., Annexon, Inc., Aerpio Therapeutics LLC, ProCertus BioPharm, Inc., Bionano Genomics, Inc., Novartis Services, Inc., ImaginAb, Inc., Icebreaker Health, Inc., Expansion Therapeutics, Inc., TScan Therapeutics, Inc., Renovacor Holdings, Inc., and Novartis Venture Fund.
Former roles also include Independent Director at Galera Therapeutics, Inc. (2012–2019), Independent Director at Tokai Pharmaceuticals, Inc. (2009–2014), Director-Special Projects at Novartis Institutes for Biomedical Research, Inc. (2004–2005), Director at Akebia Therapeutics, Inc. (2008–2013), and Partner at Agent Capital LLC (2023–2024).
Education includes an MBA from Harvard Business School and graduate studies at Harvard Kennedy School of Government.

Campbell Murray active positions

Companies	Position	Start
LUMOS PHARMA, INC.	Director/Board Member	-
Neurovance, Inc. Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that develops treatments for central nervous system disorders	Director/Board Member	-
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Private Equity Investor	2010-11-03
BioRelix, Inc. BioRelix, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of antibiotics	Director/Board Member	-

All active positions of Campbell Murray

Former positions of Campbell Murray

Companies	Position	End
Agent Capital LLC Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments.	Private Equity Investor	2024-05-30
GALERA THERAPEUTICS, INC.	Director/Board Member	2019-11-05
Tokai Pharmaceuticals, Inc. Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases	Director/Board Member	2014-10-15
Novartis Institutes for Biomedical Research, Inc. Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches	Corporate Officer/Principal	2005-06-30
Alios BioPharma, Inc. Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases	Director/Board Member	-

See the detail of Campbell Murray's experience

Training of Campbell Murray

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Campbell Murray's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	25
BioRelix, Inc. BioRelix, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of antibiotics	Health Technology
Alios BioPharma, Inc. Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases	Health Technology
Rein Therapeutics, Inc. Rein Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops stapled peptide drugs	Health Technology
Annexon, Inc. Annexon, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for neurodegenerative and autoimmune disorders	Health Technology
Aerpio Therapeutics LLC Aerpio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases	Health Technology
Neurovance, Inc. Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that develops treatments for central nervous system disorders	Commercial Services
Galera Therapeutics, Inc. Galera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs to reduce normal tissue toxicity from radiotherapy	Health Technology
Novartis Venture Funds Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors.	Finance
Tokai Pharmaceuticals, Inc. Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases	Health Technology
ProCertus BioPharm, Inc. ProCertus BioPharm, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-based pharmaceutical company	Health Technology
Novartis Institutes for Biomedical Research, Inc. Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches	Commercial Services
Akebia Therapeutics, Inc. Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases	Health Technology
Bionano Genomics, Inc. Bionano Genomics, Inc. BiotechnologyHealth Technology Develops technologies for analysis of large biological molecules	Health Technology
Novartis Services, Inc. Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company	Health Technology
Euthymics Bioscience, Inc. Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Develops a novel medicine for alcohol use disorder (AUD) and smoking cessation	Commercial Services
Novartis Venture Funds (USA) Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors	Finance
ImaginAb, Inc. ImaginAb, Inc. Medical SpecialtiesHealth Technology Engages in developing radiopharmaceutical and imaging agent products	Health Technology
Harvard Business School Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Harvard Kennedy School of Government Harvard Kennedy School of Government Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Icebreaker Health, Inc. Icebreaker Health, Inc. Medical/Nursing ServicesHealth Services Provides telehealth services	Health Services
Expansion Therapeutics, Inc. Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as drug discovery and development company for RNA-mediated diseases	Health Technology
Agent Capital LLC Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments.	Finance
TScan Therapeutics, Inc. TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients	Health Technology
Renovacor Holdings, Inc. Renovacor Holdings, Inc. BiotechnologyHealth Technology Develops transformative gene therapy	Health Technology
Lumos Pharma, Inc. Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases	Health Technology